We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sprout Pharmaceuticals Hit With FDA Warning Letter Over Advertising of Addyi
Sprout Pharmaceuticals Hit With FDA Warning Letter Over Advertising of Addyi
FDA’s Office of Prescription Drug Promotion (ODOP) slapped Sprout Pharmaceuticals with a warning letter over the misbranding of its drug Addyi (flibanserin) in a direct-to-consumer radio ad.